New drug cocktail shows promise for Tough-to-Treat uterine cancer
NCT ID NCT03694262
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tested a combination of three drugs—rucaparib, bevacizumab, and atezolizumab—in 30 people with recurrent or progressive endometrial cancer that had not responded to prior treatments. The goal was to see if the combination could shrink tumors or slow the cancer's growth. The study is now complete, and results will help determine if this approach is worth testing in larger trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rucaparib, bevacizumab, and atezolizumab (drug combination)
- What this could lead to
- If successful, this drug combination could offer a new treatment option for people with recurrent endometrial cancer that has stopped responding to standard therapies.
- What could go wrong
- This is a small, early-phase trial (30 people) without a comparison group, so results may not apply broadly. The combination may cause significant side effects and may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, 53226, United States
-
Mount Sinai
New York, New York, 10029, United States
-
St. Luke's Hospital and Health Network
Bethlehem, Pennsylvania, 18015, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Can immunotherapy plus hormones spare the womb in early endometrial cancer?
- Can a new drug tackle Hard-to-Treat gynecologic cancers?
- Can a pill restore the Body's tumor suppressor to fight multiple cancers?
- Can a Two-Drug combo tame a rare and aggressive gynecologic cancer?